arrow
E

Etto C. Eringa

Amsterdam UMC
H指数:38
被引数:5,350

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation

持续性心房颤动伴代谢合并症的患者,其心房心外膜脂肪组织的炎症状态发生改变,这与CT衰减值相关。

2025-12-260
OAAI
Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions

Troxerutin 是一种具有心血管保护作用的腹膜透析新型渗透剂。

2025-12-010
OA
Plasma Metabolite N-Formylmethionine Is Associated With Higher Blood Pressure in the Multiethnic HELIUS Cohort and Triggers Vascular Dysfunction

血浆代谢物N-甲酰甲硫氨酸与多民族HELIUS队列中的高血压相关,并引发血管功能障碍

2025-11-010
PRE
Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial

角鲨烯对射血分数保留的心力衰竭患者舒张功能和微血管功能的影响:一项2期、随机、安慰剂对照、交叉试验

2025-07-280
OAAI
Geranylgeranylacetone as Prevention for Postoperative Atrial Fibrillation (GENIALITY)

法尼基法尼基乙酰苯作为预防术后心房颤动(GENIALITY)

2025-04-140
OA
The role of myocardial blood volume in the pathophysiology of angina with non-obstructed coronary arteries: The MICORDIS study

心肌血容量在无阻塞冠状动脉心绞痛的病理生理中的作用: MICORDIS研究

2024-11-011
OAAI
Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers A clinical consensus statement from the European Society of Cardiology Working Group on Coronary Pathophysiology and Micro-circulation

血管周围脂肪组织作为治疗靶点和临床生物标志物的来源欧洲心脏病学会冠状动脉病理生理学和微循环工作组的临床共识声明

2023-08-2145
OA
Presence of Coronary Endothelial Dysfunction, Coronary Vasospasm, and Adenosine-Mediated Vasodilatory Disorders in Patients With Ischemia and Nonobstructive Coronary Arteries
2022-08-0125
OA
Glucose-mediated insulin secretion is improved in FHL2-deficient mice and elevated FHL2 expression in humans is associated with type 2 diabetes

FHL2-deficient小鼠葡萄糖介导的胰岛素分泌得到改善,人类FHL2表达升高与2型糖尿病相关

2022-07-087
OAAI
Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases: a position paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation

肠道菌群和心血管疾病的机制,治疗意义和方法学挑战: ESC冠状动脉病理生理学和微循环工作组的立场文件

2022-04-1431
OAAI